Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in inv'asive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone

被引:0
作者
Mylonas, I
Makovitzky, J
Jeschke, U
Briese, V
Friese, K
Gerber, B
机构
[1] Univ Munich, Dept Obstet & Gynecol 1, D-80337 Munich, Germany
[2] Univ Rostock, Dept Gynecol & Obstet, Rostock, Germany
关键词
breast cancer; Her2/neu; steroid receptors; Ki67; p53; DCIS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: (a) To assess the expression patterns of HER2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive ductal cancer (IDC) and IDC associated with carcinoma in situ (IDC/DCIS) and (b) to determine if there is a differential expression of these molecular markers between IDC and IDC/DCIS. Materials and Methods: Paraffin-fixed breast cancer samples, diagnosed with only one histological invasive tumor (IDC (n = 130), and IDC/DCIS (n = 36) were analyzed by immunohistochemical means. The non-parametric Mann-Whitney and chi(2) tests were used to evaluate any statistical differences between different groups. Significance was assumed at p < 0.05. Results: A significant increase of the tumor grading was observed between IDC and IDC/DCIS (p < 0.05). Her2/neu amplification was demonstrated in 49.6% of IDC compared to 31% of IDC/DCIS (p < 0.05). ER expression showed no statistical differences between IDC and IDC/DCIS. The PR expression was demonstrated in 71% of IDC with significantly lower intensity than IDC/DCIS (p < 0.05). The Ki67 expression was significantly higher (p < 0.05) in IDC cases (64%) versus IDC/DCIS (49.7%). No differences were observed between IDC and IDC/DCIS for p53 expression. Conclusion: We demonstrated significantly different expression patterns of Her2/neu, PR and Ki67 in IDC versus IDC/DCIS. Since these molecular markers play important roles in carcinogenesis and tumor progression, IDC/DCIS could be an important subtype of mammary invasive ductal cancer. Differences in expression of the evaluated markers might suggest a higher malignant potential of invasive carcinomas alone. The lower expression of Her2/neu and Ki67 in IDC/DCIS could implicate a less malignant behavior compared to a differentiated IDC. Additionally, these results might suggest that DCIS might be a malignant preform and the interaction with neoplastic tissue could result in an aggressive type of invasive tumor.
引用
收藏
页码:1719 / 1723
页数:5
相关论文
共 32 条
[1]   HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].
ALLRED, DC ;
CLARK, GM ;
TANDON, AK ;
MOLINA, R ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, M ;
EUDEY, L ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605
[2]   OVEREXPRESSION OF HER-2 NEU AND ITS RELATIONSHIP WITH OTHER PROGNOSTIC FACTORS CHANGE DURING THE PROGRESSION OF INSITU TO INVASIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
MOLINA, R ;
TANDON, AK ;
SCHNITT, SJ ;
GILCHRIST, KW ;
OSBORNE, CK ;
TORMEY, DC ;
MCGUIRE, WL .
HUMAN PATHOLOGY, 1992, 23 (09) :974-979
[3]   OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN - WHY DOES THIS OCCUR MORE FREQUENTLY IN DUCTAL CARCINOMA INSITU THAN IN INVASIVE MAMMARY-CARCINOMA AND IS THIS OF PROGNOSTIC-SIGNIFICANCE [J].
BARNES, DM ;
BARTKOVA, J ;
CAMPLEJOHN, RS ;
GULLICK, WJ ;
SMITH, PJ ;
MILLIS, RR .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :644-648
[4]   Estrogen receptor negative and progesterone receptor positive primary breast cancer:: Pathological characteristics and clinical outcome [J].
Bernoux, A ;
de Cremoux, P ;
Lainé-Bidron, C ;
Martin, EC ;
Asselain, B ;
Magdelénat, H .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (03) :219-225
[5]   ABNORMAL P53 IMMUNOREACTIVITY AND PROGNOSIS IN NODE-NEGATIVE BREAST CARCINOMAS WITH LONG-TERM FOLLOW-UP [J].
BOSARI, S ;
LEE, AKC ;
VIALE, G ;
HEATLEY, GJ ;
COGGI, G .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1992, 421 (04) :291-295
[6]  
Bottini A, 1996, ANTICANCER RES, V16, P3105
[7]   KI67 IMMUNOSTAINING IN PRIMARY BREAST-CANCER - PATHOLOGICAL AND CLINICAL ASSOCIATIONS [J].
BOUZUBAR, N ;
WALKER, KJ ;
GRIFFITHS, K ;
ELLIS, IO ;
ELSTON, CW ;
ROBERTSON, JFR ;
BLAMEY, RW ;
NICHOLSON, RI .
BRITISH JOURNAL OF CANCER, 1989, 59 (06) :943-947
[8]  
CROSS SA, 1982, J CLIN NEURO-OPHTHAL, V2, P5
[9]   Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Wilkie, H ;
Ballard-Barbash, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :953-958
[10]  
Gerber B, 2003, Zentralbl Gynakol, V125, P6